CervoMed Q2 net loss $6.6M; neflamapimod data supports Phase 3 DLB plan

CervoMed Inc.

Net loss $6.6M vs $6.3M YoY; cash $24.9M at June 30, 2026, runway to Q3 2027.
Grant revenue zero vs $1.8M; R&D $4.3M vs $5.1M; G&A $2.4M vs $3.3M.
AAIC data: CDR-SB improvement 0.70 (p=0.054) in pure DLB; basal forebrain atrophy slowed (p=0.028).
Neflamapimod awarded UK ILAP Innovation Passport; company pursuing partnership for Phase 3 DLB trial.
Raised ~$20.5M gross in June equity financings; ended RAS enrollment, completed nfvPPA enrollment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.